A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI0639 in Advanced Solid Tumors
by on Monday, April 16th, 2012 | No Comments
Condition: Solid Tumors
Intervention: Biological: MEDI0639
Sponsor: MedImmune LLC
Recruiting – verified April 2012
Excerpt from: A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI0639 in Advanced Solid Tumors